PetPeptideScholar
Evidence-first peptide education for veterinary professionals. Structured reference for peptide research in canine, feline, and equine contexts, with explicit evidence boundaries and extra-label use disclaimers on every surface.
Species-specific evidence
Canine, feline, and equine references stay separated so mechanism notes and evidence gaps remain explicit.
Regulatory boundaries
Every route is framed around extra-label use constraints, VCPR expectations, and market-specific compounding limits.
Veterinary-only posture
This surface is written for clinicians and pharmacists, not owners shopping for products or protocols.
Browse by Species
Each species page keeps the research boundaries visible before treatment or compounding decisions are discussed.
Canines
6 peptides with veterinary relevance
Felines
4 peptides with veterinary relevance
Equines
3 peptides with veterinary relevance
Veterinary Peptide Directory
These summaries are written as evidence references, not treatment recommendations. Each card keeps species coverage, evidence level, and legal friction visible.
BPC-157 (Veterinary)
Extensive animal studies (primarily rodents) show accelerated healing of tendons, ligaments, muscle, bone, and gastric mucosa. No published veterinary clinical trials in dogs, cats, or horses. All evidence is extrapolated from rodent models. FDA placed BPC-157 on the Category 2 compounding prohibited list in 2024. This applies to veterinary compounding as well. Obtaining BPC-157 for veterinary use may be legally and practically difficult in the US.
TB-500 (Veterinary)
TB-500 (thymosin beta-4 fragment) has been studied in animal models for wound healing and angiogenesis. No published controlled trials in dogs, cats, or horses. Mechanism data from cell culture and rodent studies only.
GHK-Cu (Veterinary)
GHK-Cu has documented wound-healing effects in vitro and in small animal models. Some veterinary topical products contain copper peptides. No controlled veterinary clinical trials published. No veterinary data exists for injectable or systemic GHK-Cu use. Only topical application has any theoretical basis in veterinary wound care.
Thymalin (Veterinary)
Thymic peptides have been studied in aged animals, primarily in Soviet-era Russian literature that has not been replicated in Western peer-reviewed journals. No modern veterinary clinical trials exist. Evidence quality is extremely limited.
Selank (Veterinary)
Selank is an anxiolytic peptide studied in rodent models. No published veterinary behavioral trials. Mechanism involves modulation of enkephalins and GABA systems, which are conserved across mammals.
Semax (Veterinary)
Semax is a nootropic peptide studied in rodent models for neuroprotection and cognitive enhancement. No published trials in dogs with cognitive dysfunction syndrome. BDNF/trkB mechanism may be relevant to canine brain aging.
LL-37 (Veterinary)
LL-37 is a human cathelicidin antimicrobial peptide with broad-spectrum activity demonstrated in vitro. Veterinary relevance is theoretical — no published clinical trials in animals. Natural cathelicidins exist in most mammals.
Regulatory Context
Veterinary peptide use remains an extra-label and compounding-sensitive area. These notes frame the legal environment before any clinical interpretation is made.
Extra-label use is permitted under AMDUCA by licensed veterinarians within a valid VCPR. No FDA-approved peptide drugs for animals are listed here.
The cascade system applies. Veterinary compounding is restricted, and a veterinary surgeon must determine that no authorized product is suitable.
Compounding rules vary by country. No centralized peptide approvals exist for the veterinary uses discussed here, so national authorities govern extra-label handling.
Species-first reference surface
This route now behaves like a distinct veterinary subsite instead of a generic content page, which is the same structure we should apply to the other specialty surfaces.
Open the veterinary directory